Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Moodys
Medtronic
Mallinckrodt
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

COPIKTRA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Copiktra patents expire, and what generic alternatives are available?

Copiktra is a drug marketed by Verastem Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and thirty patent family members in thirty countries.

The generic ingredient in COPIKTRA is duvelisib. One supplier is listed for this compound. Additional details are available on the duvelisib profile page.

Summary for COPIKTRA
International Patents:130
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 55
Patent Applications: 111
DailyMed Link:COPIKTRA at DailyMed
Drug patent expirations by year for COPIKTRA
Generic Entry Opportunity Date for COPIKTRA
Generic Entry Date for COPIKTRA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for COPIKTRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Johnson and Johnson
AstraZeneca
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.